{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:32:25Z","timestamp":1784287945316,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). Women diagnosed with DCIS (<jats:italic>N<\/jats:italic>\u2009=\u200928,003) or stage I\u2013III BC (N\u2009=\u2009275,836) between 1989 and 2017 were identified from the nationwide Netherlands Cancer Registry. Cumulative incidences were estimated, accounting for competing risks, and hazard ratios (HRs) for metachronous invasive CBC. To evaluate effects of adjuvant systemic therapy and screening, separate analyses were performed for stage I BC without adjuvant systemic therapy and by mode of first BC detection. Multivariable models including clinico-pathological and treatment data were created to assess CBC risk prediction performance in DCIS patients. The 10-year cumulative incidence of invasive CBC was 4.8% for DCIS patients (CBC\u2009=\u20091334). Invasive CBC risk was higher in DCIS patients compared with invasive BC overall (HR\u2009=\u20091.10, 95% confidence interval (CI)\u2009=\u20091.04\u20131.17), and lower compared with stage I BC without adjuvant systemic therapy (HR\u2009=\u20090.87; 95% CI\u2009=\u20090.82\u20130.92). In patients diagnosed \u22652011, the HR for invasive CBC was 1.38 (95% CI\u2009=\u20091.35\u20131.68) after screen-detected DCIS compared with screen-detected invasive BC, and was 2.14 (95% CI\u2009=\u20091.46\u20133.13) when not screen-detected. The C-index was 0.52 (95% CI\u2009=\u20090.50\u20130.54) for invasive CBC prediction in DCIS patients. In conclusion, CBC risks are low overall. DCIS patients had a slightly higher risk of invasive CBC compared with invasive BC, likely explained by the risk-reducing effect of (neo)adjuvant systemic therapy among BC patients. For support of clinical decision making more information is needed to differentiate CBC risks among DCIS patients.<\/jats:p>","DOI":"10.1038\/s41523-020-00202-8","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T11:02:41Z","timestamp":1604401361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer"],"prefix":"10.1038","volume":"6","author":[{"given":"Daniele","family":"Giardiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-3762","authenticated-orcid":false,"given":"Iris","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-4935","authenticated-orcid":false,"given":"Esther H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"de Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-429X","authenticated-orcid":false,"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"202_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1054\/bjoc.2000.1603","volume":"84","author":"HS Evans","year":"2001","unstructured":"Evans, H. S. et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br. J. Cancer 84, 435\u2013440 (2001).","journal-title":"Br. J. Cancer"},{"key":"202_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-005-4016-2","volume":"93","author":"I Soerjomataram","year":"2005","unstructured":"Soerjomataram, I. et al. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001. Breast Cancer Res. Treat. 93, 91\u201395 (2005).","journal-title":"Breast Cancer Res. Treat."},{"key":"202_CR3","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/0959-8049(93)90013-6","volume":"29A","author":"H Brenner","year":"1993","unstructured":"Brenner, H., Siegle, S., Stegmaier, C. & Ziegler, H. Second primary neoplasms following breast cancer in Saarland, Germany, 1968-1987. Eur. J. Cancer 29A, 1410\u20131414 (1993).","journal-title":"Eur. J. Cancer"},{"key":"202_CR4","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1245\/s10434-015-4442-2","volume":"22","author":"PR Portschy","year":"2015","unstructured":"Portschy, P. R. et al. Perceptions of contralateral breast cancer risk: a prospective, longitudinal study. Ann. Surg. Oncol. 22, 3846\u20133852 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"202_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1470-2045(05)70174-1","volume":"6","author":"M Hartman","year":"2005","unstructured":"Hartman, M. et al. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol. 6, 377\u2013382 (2005).","journal-title":"Lancet Oncol."},{"key":"202_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jnci\/djz010","volume":"111","author":"I Kramer","year":"2019","unstructured":"Kramer, I. et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J. Natl. Cancer Inst. 111, 709\u2013718 (2019).","journal-title":"J. Natl. Cancer Inst."},{"key":"202_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00432-015-2031-1","volume":"142","author":"J Prater","year":"2016","unstructured":"Prater, J., Valeri, F., Korol, D., Rohrmann, S. & Dehler, S. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry. J. Cancer Res. Clin. Oncol. 142, 365\u2013371 (2016).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"202_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2011","unstructured":"Nichols, H. B., Berrington de Gonzalez, A., Lacey, J. V. Jr., Rosenberg, P. S. & Anderson, W. F. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J. Clin. Oncol. 29, 1564\u20131569 (2011).","journal-title":"J. Clin. Oncol."},{"key":"202_CR9","unstructured":"Netherlands Cancer Registry (NCR). Survival and prevalence of cancer. https:\/\/www.cijfersoverkanker.nl (2016)."},{"key":"202_CR10","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","volume":"94","author":"VL Ernster","year":"2002","unstructured":"Ernster, V. L. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J. Natl. Cancer Inst. 94, 1546\u20131554 (2002).","journal-title":"J. Natl. Cancer Inst."},{"key":"202_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-016-3973-y","volume":"159","author":"LE Elshof","year":"2016","unstructured":"Elshof, L. E. et al. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res. Treat. 159, 553\u2013563 (2016).","journal-title":"Breast Cancer Res. Treat."},{"key":"202_CR12","doi-asserted-by":"crossref","unstructured":"Mariotti, C. Ductal Carcinoma in Situ of the Breast. Springer International Publishing (2018).","DOI":"10.1007\/978-3-319-57451-6"},{"key":"202_CR13","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1245\/s10434-017-5931-2","volume":"24","author":"ME Miller","year":"2017","unstructured":"Miller, M. E. et al. Contralateral breast cancer risk in women with ductal carcinoma in situ: is it high enough to justify bilateral mastectomy? Ann. Surg. Oncol. 24, 2889\u20132897 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"202_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1200\/JCO.2008.20.1681","volume":"27","author":"TM Tuttle","year":"2009","unstructured":"Tuttle, T. M. et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J. Clin. Oncol. 27, 1362\u20131367 (2009).","journal-title":"J. Clin. Oncol."},{"key":"202_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10549-011-1531-1","volume":"129","author":"RS Falk","year":"2011","unstructured":"Falk, R. S., Hofvind, S., Skaane, P. & Haldorsen, T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res. Treat. 129, 929\u2013938 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"202_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0960-9776(03)00152-8","volume":"12","author":"EB Claus","year":"2003","unstructured":"Claus, E. B., Stowe, M., Carter, D. & Holford, T. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 12, 451\u2013456 (2003).","journal-title":"Breast"},{"key":"202_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao, X., Fisher, S. G. & Emami, B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J. Radiat. Oncol. Biol. Phys. 56, 1038\u20131045 (2003).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"202_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-016-4039-x","volume":"161","author":"M Chowdhury","year":"2017","unstructured":"Chowdhury, M., Euhus, D., Onega, T., Biswas, S. & Choudhary, P. K. A model for individualized risk prediction of contralateral breast cancer. Breast Cancer Res. Treat. 161, 153\u2013160 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"202_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-018-4763-5","volume":"170","author":"M Chowdhury","year":"2018","unstructured":"Chowdhury, M. et al. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res. Treat. 170, 415\u2013423 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"202_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","volume":"44","author":"D Akdeniz","year":"2018","unstructured":"Akdeniz, D. et al. Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast 44, 1\u201314 (2018).","journal-title":"Breast"},{"key":"202_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0726-0","volume":"18","author":"R Langballe","year":"2016","unstructured":"Langballe, R. et al. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Res. 18, 65 (2016).","journal-title":"Breast Cancer Res."},{"key":"202_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/jnci\/djr043","volume":"103","author":"S Mook","year":"2011","unstructured":"Mook, S. et al. Independent prognostic value of screen detection in invasive breast cancer. J. Natl. Cancer Inst. 103, 585\u2013597 (2011).","journal-title":"J. Natl. Cancer Inst."},{"key":"202_CR23","doi-asserted-by":"publisher","unstructured":"Giardiello, D. et al. Data and metadata supporting the published article: contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. https:\/\/doi.org\/10.6084\/m9.figshare.12982424 (2020).","DOI":"10.6084\/m9.figshare.12982424"},{"key":"202_CR24","unstructured":"Oncoline. Borstkanker. Landelijke richtlijn, Versie: 2.0. https:\/\/www.oncoline.nl\/ (Aug 2020 data last accessed)."},{"key":"202_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","volume":"34","author":"AJ van den Broek","year":"2016","unstructured":"van den Broek, A. J. et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers. J. Clin. Oncol. 34, 409\u2013418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"202_CR26","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"202_CR27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jama.293.8.964","volume":"293","author":"EB Claus","year":"2005","unstructured":"Claus, E. B., Petruzella, S., Matloff, E. & Carter, D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293, 964\u2013969 (2005).","journal-title":"JAMA"},{"key":"202_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","volume":"9","author":"D Thompson","year":"2004","unstructured":"Thompson, D. & Easton, D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia 9, 221\u2013236 (2004).","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"202_CR29","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","volume":"14","author":"JA Murphy","year":"2013","unstructured":"Murphy, J. A., Milner, T. D. & O\u2019Donoghue, J. M. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol. 14, e262\u2013e269 (2013).","journal-title":"Lancet Oncol."},{"key":"202_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"13","author":"NN Basu","year":"2015","unstructured":"Basu, N. N., Ross, G. L., Evans, D. G. & Barr, L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J. Surg. Oncol. 13, 237 (2015).","journal-title":"World J. Surg. Oncol."},{"key":"202_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12609-018-0271-1","volume":"10","author":"M O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell, M. Estimating contralateral breast cancer risk. Curr. Breast Cancer Rep. 10, 91\u201397 (2018).","journal-title":"Curr. Breast Cancer Rep."},{"key":"202_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10549-013-2588-9","volume":"139","author":"A Font-Gonzalez","year":"2013","unstructured":"Font-Gonzalez, A. et al. Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 139, 811\u2013819 (2013).","journal-title":"Breast Cancer Res Treat."},{"key":"202_CR33","doi-asserted-by":"crossref","unstructured":"Brierley, J. D., Gospodarowicz, M. K. & Wittekind, C. TNM classification of malignant tumours. 8th edn (Wiley-Blackwell, 2017).","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"202_CR34","unstructured":"Foundation Federation of Dutch Medical Scientific Societies. Human Tissue and Medical Research: Code of Conduct for responsible use (Federa, 2011)."},{"key":"202_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jclinepi.2012.09.017","volume":"66","author":"A Latouche","year":"2013","unstructured":"Latouche, A., Allignol, A., Beyersmann, J., Labopin, M. & Fine, J. P. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J. Clin. Epidemiol. 66, 648\u2013653 (2013).","journal-title":"J. Clin. Epidemiol."},{"key":"202_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17453674.2018.1427314","volume":"89","author":"S Van Der Pas","year":"2018","unstructured":"Van Der Pas, S., Nelissen, R. & Fiocco, M. Different competing risks models for different questions may give similar results in arthroplasty registers in the presence of few events. Acta Orthop. 89, 145\u2013151 (2018).","journal-title":"Acta Orthop."},{"key":"202_CR37","unstructured":"RIVM. Breast Cancer screening program; facts and figures. https:\/\/www.rivm.nl\/en\/breast-cancer-screening-programme\/background\/facts-and-figures (May 2020, date last accessed)."},{"key":"202_CR38","unstructured":"IKNL. National evaluation of breast cancer screening in the Netherlands 2017\/2018. https:\/\/www.iknl.nl\/getmedia\/8b019b63-0eb1-4afa-a824-31c4d10cc86e\/Breast_cancer_screening_in_the_Netherlands_2017-2018_en.pdf (Aug 2020, date last accessed)."},{"key":"202_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4122-2","volume":"18","author":"VDV Sankatsing","year":"2018","unstructured":"Sankatsing, V. D. V. et al. Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening. BMC Cancer 18, 256 (2018).","journal-title":"BMC Cancer"},{"key":"202_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/1055-9965.EPI-12-1050","volume":"22","author":"X Xue","year":"2013","unstructured":"Xue, X. et al. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. Cancer Epidemiol. Biomark. Prev. 22, 275\u2013285 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"202_CR41","doi-asserted-by":"crossref","unstructured":"Harrell, F. E., Jr. Regression Modeling Strategies with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd edn (Springer Series in Statistics, 2015).","DOI":"10.1007\/978-3-319-19425-7"},{"key":"202_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/bimj.200800228","volume":"51","author":"JA Koziol","year":"2009","unstructured":"Koziol, J. A. & Jia, Z. The concordance index C and the Mann-Whitney parameter Pr(X>Y) with randomly censored data. Biom. J. 51, 467\u2013474 (2009).","journal-title":"Biom. J."},{"key":"202_CR43","doi-asserted-by":"crossref","unstructured":"Van Buuren, S. Flexible imputation of missing data. 2nd edn (Chapman and Hall\/CRC, 2018).","DOI":"10.1201\/9780429492259"},{"key":"202_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","volume":"110","author":"P Madley-Dowd","year":"2019","unstructured":"Madley-Dowd, P., Hughes, R., Tilling, K. & Heron, J. The proportion of missing data should not be used to guide decisions on multiple imputation. J. Clin. Epidemiol. 110, 63\u201373 (2019).","journal-title":"J. Clin. Epidemiol."},{"key":"202_CR45","unstructured":"R: A Language and Environment for Statistical Computing (R: Foundation for Statistical Computing, 2020)."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-020-00202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-020-00202-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-020-00202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:57:45Z","timestamp":1670295465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-020-00202-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1038\/s41523-020-00202-8","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}